BOSTON (

TheStreet

) --More hepatitis data supposedly kept under wraps by the

European Association for the Study of the Liver

(EASL) in advance of next week's closely followed annual meeting has made its way into the hands of Wall Street investors.

Fortunately for EASL, the leaked research abstracts, including one describing the important "Electron" study of

Gilead Sciences'

(GILD) - Get Report

hepatitis C drug GS-7977, doesn't contain new information and therefore isn't particularly stock moving.

On Tuesday, an investor who asked to remain anonymous emailed me three research abstracts involving hepatitis C drug data from Gilead Sciences and

Bristol-Myers Squibb

(BMY) - Get Report

. All of the abstracts were supposed to be embargoed and therefore not publicly available, according to EASL rules.

One of these abstracts, titled "Electron: Once Daily PSI-7977 Plus RBV in HCV GT1/2/3" is the subject of intense investor interest because it will help assess the efficacy of Gilead's most important hepatitis C drug, acquired through the $11 billion acquisition of Pharmasset.

EASL officials confirmed the authenticity of the leaked research abstracts via email but requested that specific information contained in the abstracts not be disclosed. I'm abiding by EASL's request because the leaked abstracts are not much more than placeholders containing early, incomplete and previously announced data that will only be updated at the EASL meeting April 18-22.

The embargoed abstract for Gilead's Electron study, for example, describes but doesn't contain any specific data on response rates involving GS-7977 and treatment-naive, genotype 1 hepatitis C patients. The performance of GS-7977 in this group of hepatitis C patients is among the most highly anticipated data presentations expected at the EASL meeting.

The EASL meeting is where Gilead Sciences, Bristol,

Abbott

(ABT) - Get Report

,

Idenix Pharmaceuticals

(IDIX)

,

Vertex Pharmaceuticals

(VRTX) - Get Report

and

Johnson & Johnson

(JNJ) - Get Report

are among the companies expected to present new clinical data on experimental hepatitis C therapies. Therefore, the meeting is as vitally important to hepatitis C doctors and patients as it is to investors.

TheStreet Recommends

How a select set of confidential, embargoed hepatitis C drug abstracts came into the hands of some Wall Street investors hasn't been fully explained. The blame most likely lies with EASL, which apparently failed to wall off the select set of abstracts when the group posted most of the abstracts online April 4. EASL later realized its error and was able to yank the embargoed abstracts from its web site, but not before some people, including some investors, were able to download them.

On Monday, a sell-side analyst working for Jefferies

published a research note

describing data from another leaked EASL abstract concerning a mid-stage study of Bristol's daclatasvir and Gilead's GS-7977.

The multiple research abstract leaks are another black eye for EASL, which has come under

criticism for the way it handles potential market-moving hepatitis C clinical data

in advance of its annual meeting. EASL's original plan to selectively disclose abstracts to its members or registered attendees of the annual meeting -- a group which includes hedge fund/mutual fund portfolio managers and sell-side analysts -- was criticized as

misguided, unfair, unworkable

.

EASL quickly reversed its policy

, choosing instead of make most of the research abstracts for its meeting publicly available to everyone on April 4. But at the same time, EASL chose to keep 20 abstracts under embargo until the start of the meeting.

That plan, too has gone awry. EASL is leaking like a sieve.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.